2013
Translation of Biomedical Prevention Strategies for HIV
Vermund SH, Tique JA, Cassell HM, Pask ME, Ciampa PJ, Audet CM. Translation of Biomedical Prevention Strategies for HIV. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2013, 63: s12-s25. PMID: 23673881, PMCID: PMC3725750, DOI: 10.1097/qai.0b013e31829202a2.Peer-Reviewed Original ResearchConceptsPrevention of motherPrevention strategiesClean injection equipmentChild HIV transmissionBiomedical approachBiomedical prevention strategiesRisk of acquisitionHIV prevention strategiesBehavioral risk reductionHigh-prevalence regionsRisk of transmissionCircumcision of menBlood product safetyChild transmissionHIV transmissionAntiretroviral drugsPrevalence regionsHIV preventionHIVFamily planningMore childrenPreventionRisk reductionInjection equipmentSaharan Africa
2001
Vaccine Efficacy Trials for Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome Are Feasible in the United States: A Commentary on the HIVNET Vaccine Preparedness Study
Vermund SH. Vaccine Efficacy Trials for Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome Are Feasible in the United States: A Commentary on the HIVNET Vaccine Preparedness Study. American Journal Of Epidemiology 2001, 153: 628-631. PMID: 11282788, DOI: 10.1093/aje/153.7.628.Peer-Reviewed Original Research
1998
Rationale for the testing and use of a partially effective HIV vaccine.
Vermund SH. Rationale for the testing and use of a partially effective HIV vaccine. AIDS Research And Human Retroviruses 1998, 14 Suppl 3: s321-3. PMID: 9814960.Peer-Reviewed Original ResearchImmunological and Virological Analyses of Persons Infected by Human Immunodeficiency Virus Type 1 while Participating in Trials of Recombinant gp120 Subunit Vaccines
Connor RI, Korber B, Graham BS, Hahn BH, Ho DD, Walker BD, Neumann AU, Vermund SH, Mestecky J, Jackson S, Fenamore E, Cao Y, Gao F, Kalams S, Kunstman KJ, McDonald D, McWilliams N, Trkola A, Moore JP, Wolinsky SM. Immunological and Virological Analyses of Persons Infected by Human Immunodeficiency Virus Type 1 while Participating in Trials of Recombinant gp120 Subunit Vaccines. Journal Of Virology 1998, 72: 1552-1576. PMID: 9445059, PMCID: PMC124637, DOI: 10.1128/jvi.72.2.1552-1576.1998.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus type 1Immunodeficiency virus type 1Virus type 1MN rgp120Antibody responseHIV-1Recombinant gp120 subunit vaccinePhase I/II clinical trialsCytotoxic T lymphocyte responsesType 1Immunoglobulin G antibody responseGp120 subunit vaccineSyncytium-inducing (SI) phenotypeT lymphocyte responsesG antibody responseClade B virusesInducing (NSI) phenotypeInfected vaccineesNSI strainsPlacebo recipientsVaccine recipientsViral burdenPlacebo vaccineAntibody titersMultiple immunizationsAnalysis of Intercurrent Human Immunodeficiency Virus Type 1 Infections in Phase I and II Trials of Candidate AIDS Vaccines
Graham B, McElrath M, Connor R, Schwartz D, Gorse G, Keefer M, Mulligan M, Matthews T, Wolinsky S, Montefiori D, Vermund S, Lambert J, Corey L, Belshe R, Dolin R, Wright P, Korber B, Wolff M, Fast P, Group A. Analysis of Intercurrent Human Immunodeficiency Virus Type 1 Infections in Phase I and II Trials of Candidate AIDS Vaccines. The Journal Of Infectious Diseases 1998, 177: 310-309. PMID: 9466516, DOI: 10.1086/514209.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS VaccinesAmino Acid SequenceCD4 Lymphocyte CountFemaleHIV AntibodiesHIV Envelope Protein gp120HIV InfectionsHIV-1HumansImmunity, ActiveIncidenceMaleMiddle AgedMolecular Sequence DataNeutralization TestsPeptide FragmentsRisk-TakingSequence AnalysisSubstance Abuse, IntravenousViral LoadConceptsHIV-1 infectionHuman immunodeficiency virus type 1 (HIV-1) infectionVirus type 1 infectionCandidate AIDS vaccinesType 1 infectionAIDS vaccinePhase IHigh-risk sexual exposureVaccine-induced immune responsesComplete immunization scheduleEarly clinical courseCD4 lymphocyte countIntravenous drug useV3 loop amino acid sequencesUninfected subjectsVaccine recipientsLymphocyte countClinical courseImmunization scheduleSexual exposureVirus loadImmune responseControl groupDrug useInfection
1994
NIH conference. HIV vaccine development: a progress report.
Hoth DF, Bolognesi DP, Corey L, Vermund SH. NIH conference. HIV vaccine development: a progress report. Annals Of Internal Medicine 1994, 121: 603-11. PMID: 8085693, DOI: 10.7326/0003-4819-121-8-199410150-00008.Peer-Reviewed Original ResearchConceptsVaccine candidatesAnimal modelsHuman immunodeficiency virus (HIV) infectionCytotoxic T cell responsesLarge-scale efficacy trialsInnovative vaccine candidatesImmunodeficiency virus infectionT cell responsesCorrelates of immunityEffective preventive vaccineProtective immune responseDiversity of HIVHIV vaccine researchHuman phase IPromising vaccine candidateUseful animal modelPreventive vaccineEfficacy trialsVirus infectionImmune responseVaccine researchSuch trialsPhase ITrialsHIVThe role of prevention research in HIV vaccine trials.
Vermund SH. The role of prevention research in HIV vaccine trials. AIDS Research And Human Retroviruses 1994, 10 Suppl 2: s303-5. PMID: 7865326.Peer-Reviewed Original ResearchConceptsVaccine trialsLarge-scale vaccine trialsHIV vaccine efficacy trialsPrevention researchVaccine efficacy trialsHIV vaccine trialsPrevention clinical trialsHIV prevention researchSexual transmissionClinical trialsEfficacy trialsNeedle useHIV researchInfectious diseasesBlood contaminationPotential trial sitesTrialsNational InstituteObservational researchTrial sitesSame criteriaPrevention technologiesAllergyVaccineInfection